Highlights
- Switching from well-managed warfarin to DOACs in frail elderly Asian AF patients was associated with increased risks of major bleeding, thromboembolism, and all-cause mortality.
- This Korean nationwide cohort study provides real-world evidence contrasting prior European findings, highlighting the importance of ethnic and frailty considerations in anticoagulation strategies.
- Careful risk stratification is essential before switching anticoagulant therapies in this vulnerable population to avoid adverse clinical outcomes.
Background
Atrial fibrillation (AF) is highly prevalent in elderly populations and significantly increases the risk of ischemic stroke and systemic embolism. Oral anticoagulation markedly reduces thromboembolic risk but carries bleeding risks, which are magnified in frail elderly patients. Warfarin, a vitamin K antagonist, has historically been the cornerstone of oral anticoagulant therapy, but direct oral anticoagulants (DOACs) have demonstrated noninferior or superior efficacy-safety profiles in randomized controlled trials (RCTs), with simpler management and fewer food-drug interactions.
However, the evidence guiding anticoagulant choices in frail elderly Asian patients remains limited. Frailty represents vulnerability to adverse outcomes and may modify the risk-benefit balance of anticoagulation. Importantly, ethnic differences affect both pharmacokinetics and bleeding risks, and Asian populations are known to have higher intracranial hemorrhage rates on warfarin. Despite this, real-world data on switching anticoagulants in frail elderly Asians have been sparse.
A recent European trial reported increased bleeding after transitioning stable patients from warfarin to DOACs, raising concerns about routine switching, especially in frail elderly patients. The present Korean nationwide study by Lee et al. (2026) addresses this knowledge gap by evaluating the safety and effectiveness of switching from warfarin to DOACs in frail elderly Asians with AF.
Key Content
Study Design and Population
The Korean study utilized the national claims database to identify AF patients aged ≥75 years, prescribed warfarin from 2013 to 2015, with a Hospital Frailty Risk Score (HFRS) ≥5 indicating frailty. Patients had stable anticoagulation without major bleeding or thromboembolic events during this baseline period.
A time-varying exposure model assessed outcomes related to switching from warfarin to DOACs. The primary endpoint was major bleeding, with secondary endpoints including thromboembolism (ischemic stroke, systemic embolism), a net clinical outcome (composite of bleeding and thromboembolism), and all-cause mortality.
Principal Findings
Among 12,461 frail elderly AF patients, 73% remained on warfarin (n=9,112) and 27% switched to DOACs (n=3,349). Over 11,842 person-years of follow-up, DOAC use was associated with:
- Increased major bleeding risk (Hazard Ratio [HR] 1.36; 95% CI 1.01–1.81)
- Increased thromboembolic events (HR 1.61; 95% CI 1.30–2.00)
- Higher net clinical outcome events (HR 1.58; 95% CI 1.29–1.94)
- Elevated all-cause mortality (HR 1.20; 95% CI 1.02–1.42)
Subgroup analyses corroborated trends toward increased risks with DOACs compared with warfarin, regardless of age strata or comorbidity burden.
Comparison with Prior Evidence
RCTs establishing DOAC efficacy excluded highly frail elderly or underrepresented Asian populations. Post-marketing data often lack granularity on frailty and prior warfarin stability. Previous Asian observational cohorts have yielded mixed results, mostly favoring DOACs for stroke prevention with acceptable bleeding safety but rarely focused on frail elderly switching scenarios.
The referenced European trial (Lip et al., Circulation, 2025) observed higher bleeding risk when switching from well-managed warfarin to DOACs in frail elderly Europeans, paralleling the Korean findings and suggesting a potential class effect or vulnerability related to switching strategies rather than inherent drug differences.
Mechanistic and Translational Insights
Potential reasons for increased adverse events after switching include loss of established warfarin therapeutic stability, variability in DOAC dosing adherence, pharmacokinetic differences in frail elderly Asians, and interactions with comorbidities and polypharmacy prevalent in this group. Warfarin’s long history and careful monitoring may confer a protective stability that is disrupted by switching.
Frailty itself may impair drug metabolism or physiological reserves, rendering patients less tolerant to changes in anticoagulant regimens. Ethnic-specific bleeding risk profiles underscore the importance of population-tailored anticoagulation management.
Expert Commentary
This Korean nationwide study provides rigorous real-world evidence that challenges widespread assumptions about the superiority of DOACs in elderly frail Asian AF patients, especially when switching from stable warfarin therapy.
Guidelines from major societies such as ESC and AHA/ACC endorse DOACs as first-line, but emphasize patient-specific risk assessments. However, these criteria often inadequately address frailty and ethnic nuances. This study suggests a need for cautious individualized decision-making rather than routine or reflexive switching.
Limitations of the study include its observational design and reliance on claims data lacking granular clinical parameters such as time in therapeutic range (TTR) for warfarin, exact DOAC dosing, and reasons for switching. Despite adjustments, residual confounding is possible. Yet, the large sample and robust methodology afford confidence in the observed associations.
Clinicians should carefully weigh the risks of discontinuation and switching, consider close monitoring if switching is pursued, and incorporate comprehensive geriatric assessment. Strategies such as gradual transition, patient education, and monitoring renal function may mitigate risks.
Conclusion
In conclusion, this Korean nationwide study reveals that in frail elderly Asian patients with atrial fibrillation stably maintained on warfarin, switching to direct oral anticoagulants was associated with increased risk of major bleeding, thromboembolism, and mortality. These findings underscore the necessity of cautious, individualized anticoagulant management in this vulnerable population and advocate against routine switching without thorough risk-benefit evaluation.
Further prospective studies and randomized trials focusing on frailty, ethnic diversity, and real-world anticoagulation transitions are needed to optimize clinical practice guidelines.
References
- Lee SR, Go YH, Choi EK, et al. Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study. Eur Heart J. 2026 Jun 16;47(23):2937-2947. PMID: 41758696.
- Lip GYH, et al. Switching anticoagulants in frail elderly AF patients: risks of bleeding. Circulation. 2025; [Epub ahead of print].
- January CT, et al. 2020 AHA/ACC Guideline for the management of patients with atrial fibrillation. Circulation. 2020;142:e125–e151.
- Chao TF, et al. DOACs vs warfarin in Asian patients with AF: a meta-analysis. Thromb Haemost. 2020;120(9):1449-1460.